Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Juno Therapeutics Stock Still a Strong Buy?


Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from two different catalysts during the month.

First off, the company provided yet another positive clinical update for its lead cell therapy, JCAR017, in relapsed and refractory aggressive B cell non-Hodgkin lymphoma (NHL) at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland.

Image source: Getty Images.

Continue reading


Source: Fool.com

Novartis AG ADR Stock

€94.80
2.160%
There is an upward development for Novartis AG ADR compared to yesterday, with an increase of €2.00 (2.160%).

Like: 0
NVS
Share

Comments